BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/19/2015 4:02:00 PM | Browse: 1423 | Download: 2678
Publication Name World Journal of Hepatology
Manuscript ID 19579
Country Japan
ISSN 1948-5182 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Topic Highlights
Article Title Antiviral therapy for chronic hepatitis B: Combination of nucleoside analogs and interferon
Manuscript Source Invited Manuscript
All Author List Satoru Hagiwara, Naoshi Nishida and Masatoshi Kudo
Funding Agency and Grant Number
Funding Agency Grant Number
Japanese Society for the Promotion of Science 24590997 (to Nishida N)
Smoking Research Foundation to Nishida N
Corresponding Author Naoshi Nishida, MD, PhD, Department of Gastroenterology and Hepatology, Kinki University School of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka 589-8511, Japan. naoshi@med.kindai.ac.jp
Key Words Hepatitis B virus; Interferon; Sequential therapy; Combination therapy; Nucleoside analog
Core Tip For the suppression of emergence of hepato-cellular carcinoma, disappearance of hepatitis B s antigen (HBsAg) is necessary, which is an important goal for the treatment of chronic hepatitis B. In order to achieve HBsAg clearance, combination therapies with nucleoside analogs (NAs) and interferon (IFN) and sequential therapies with NAs administration followed by IFN therapy have been routinely employed. The combination of antiviral agents, and the appropriate selection of patients are critical to obtain a good response for HBsAg clearance.
Publish Date 2015-10-19 16:02
Citation Hagiwara S, Nishida N, Kudo M. Antiviral therapy for chronic hepatitis B: Combination of nucleoside analogs and interferon. World J Hepatol 2015; 7(23): 2427-2431
URL http://www.wjgnet.com/1948-5182/full/v7/i23/2427.htm
DOI http://dx.doi.org/10.4254/wjh.v7.i23.2427
Full Article (PDF) WJH-7-2427.pdf
Full Article (Word) WJH-7-2427.doc